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Introduction 
  
steoporosis is a major public health 
problem worldwide and its prevalence 
is increasing. This morbidity burden has 
considerable medical, social and financial 
implications due to the fractures associated 
with the disease. Although osteoporotic 
fractures are an important cause of 
morbidity, disability and mortality, they are 
preventable. Osteoporosis is a well-estab-
lished clinical worldwide problem for 
adults. On the other hand, osteoporosis in 
children and adolescents is rather new and 
increasingly recognized with certain unique 
diagnostic and clinical challenges1-2. In fact, 
some researchers suggested that osteo-
porosis seen later in life may originate 
during childhood or adolescence years3-4.  
Osteoporosis is a systemic disorder defined 
as “decreased bone strength that 
predisposes individuals to fragility 
fractures”5. Bone strength reflects the 
integration of two main features: bone 
density and bone quality6. In children, a 
somewhat different definition exists, 
requiring both a history of pathologic 
fractures and low bone mineral content or 
density7. These criteria are fulfilled by the 
diagnosis of a single significant fracture in a 
long bone of the lower extremity, two 
fractures in the long bone of an upper 
extremity, or one vertebral compression 
fracture8-9. The relationship between bone  
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density and fracture risk is currently 
unknown in children and therefore it is not 
possible to define thresholds below which 
there is an increased fracture risk; although 
there are now several studies that have 
examined the relationship between bone 
density in healthy children and 
fractures10,11.  
Osteopenia is a term that is often confused 
with osteoporosis. Osteopenia is defined as 
a decrease in the amount of bone tissue, 
and osteoporosis is osteopenia with bone 
fragility. On the other hand, osteopenia 
should not be confused with osteomalacia 
(reduction in bone mineral with the 
accumulation of unmineralized bone 
matrix). Both osteopenia and osteomalacia 
are associated with a reduction in bone 
density and may result in bone pain and 
fracture, but their causes and management 
are quite different3. 
 
Methods 
 
An extensive literature search of English-
language electronic databases in Medline, 
PubMed, and Cochrane database of 
evidence-based reviews was performed 
starting 2000 onwards. Further articles 
were obtained from the references of the 
initial search. Keywords osteoporosis, 
children, primary osteoporosis, secondary 
osteoporosis, osteopenia, bone mineral 
density and fragility fractures were used. 
Abstracts of the relevant articles were 
scrutinized, and the pertinent articles were 
reviewed in detail. This included 
narrowing down the search for 
osteoporosis in children in various regions 
of the world concerning its classification, 
presentation, pathophysiology, diagnostic 
modalities and prevention and treatment 
options, and inference was drawn. 
 
Clinical Presentation  
A common presentation of childhood 
osteoporosis is recurrent long bone 
fractures, particularly if associated with 
low impact trauma. Vertebral compression 
fractures often present with symptoms of 
back pain and potential spinal deformity. 
Occasionally, vertebral compression 
fractures may be asymptomatic and may 
only be identified when a spinal X-ray is 
performed in a child who is being investi-
gated for a low bone density or any other 
reason. Symptomatic osteoporosis may be 
the first manifestation of an underlying 
chronic disease such as leukemia or 
Crohn’s disease12. Idiopathic juvenile 
osteoporosis (IJO) which is a rare cause of 
primary osteoporosis will often present 
with progressive symptoms of back pain 
and difficulty in walking.  
 
Causes and Classification 
 
Race and ethnicity constitute non 
modifiable risk factors for osteoporosis. 
Genetic predisposition to other systemic 
illnesses and the treatments thus 
necessitated likewise play a role in bone 
health. Childhood osteoporosis may arise 
from an intrinsic genetic bone abnormality 
(primary osteoporosis) or more commonly 
secondary to an underlying medical 
condition and/or its treatment (secondary 
osteoporosis)3,13.  
 
Primary osteoporosis 
Primary osteoporosis as defined by 
decreased bone strength that predisposes 
individuals to fragility fractures, is most 
commonly caused in children by one or 
other of the forms of osteogenesis imper-
fecta (OI)14. In OI there is an underlying 
abnormality in bone matrix composition, 
usually due to defective synthesis of type I 
collagen. The original classification by 
Sillence D, based on phenotypic features, 
consisted of four types which are varying 
in severity. Type II OI is lethal in the 
perinatal period. Type III is a severe form 
of the disease with obvious bony 
deformities and reduced bone mineral 
density (BMD). Although types I and IV are 
milder and less easily recognized, they 
should be considered in the differential 
diagnosis of children with multiple frac-
tures4,8. Collagen can often be demon-
strated with either a reduction in amount 
(type I) or quality (types II, III and IV). It is 
recognized that some children with OI do 
not clearly fall into one of these four types. 
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In recent years, three additional forms of 
OI have been identified (types V, VI, and 
VII) based on a combination of phenotypic 
and bone histological features15.  
Another example of primary osteoporosis is 
IJO which is a rare condition with an 
estimated incidence of 1 in 100,000 that is 
characteristically presents with back pain, 
difficulty walking and vertebral compres-
sion fractures usually in early puberty 
(Figure 1). Its precise cause is unclear 
although on bone histology, there is an 
evidence of reduced bone formation. 
Spontaneous resolution has been reported in 
some IJO patients while others go on to have 
a severe disability with a potential loss of 
walking ability.   
Osteoporosis pseudoglioma syndrome is a 
third very rare example in which there is a 
combination of osteoporosis, and congenital 
blindness due to failure of peripheral retina 
vascularization8.  
 
 
 
Figure 1: Vertebral compression fractures in the 
lumbar spine with osteopenia in a child with 
idiopathic juvenile osteoporosis. 
 
Secondary Osteoporosis 
Chronic systemic diseases can be 
detrimental to the growing skeleton in 
children. Chronic renal insufficiency leads 
to abnormal bone metabolism via 
disturbances in calcium and phosphate 
handling, altered vitamin D and parathyroid 
hormone (PTH) levels and function, and 
altered renal clearance of aluminum and 
other metabolites. Additional factors include 
malnutrition, metabolic acidosis, and 
anemia16. Gastrointestinal disorders such as 
celiac disease and inflammatory bowel 
disease interfere with calcium absorption 
from the gut and cause vitamin D 
insufficiency or deficiency. Liver dys-
function can affect children and may impair 
bone health through calcium and vitamin 
malabsorption, failure of vitamin D acti-
vation, bile salt deficiency, and chronic 
malnutrition12,17. 
Endocrine system disorders that result in 
inadequate or excessive levels of systemic 
hormones can negatively impact bone health 
in the growing skeleton in children. For 
example, growth hormone deficiency, 
diabetes mellitus (DM), and hyperthyroid-
dism are all risk factors for osteoporosis18,19. 
Bone turnover is altered in type 1 DM 
children, whereas BMD remains normal 
during growth. Physical activity and optimal 
calcium intakes may improve bone 
metabolism and delay osteoporosis20. Pub-
ertal hormones, especially estrogen, play a 
critical role in bone mass acquisition. Because 
the majority of BMD is accrued during the 
peripubertal years, recognition and timely 
treatment of hypogonadism are key. 
Decreased muscle development and im-
paired ambulation in children with cerebral 
palsy (CP) and muscular dystrophy 
contribute to increased risk of osteoporosis 
(Table 1)21-22. 
 
Causes of secondary osteoporosis 
 
1. Reduced mobility 
Bones develop to withstand the mechanical 
forces applied to them in everyday life. The 
magnitude of these forces and the skeleton’s 
ability to sense and respond to them have a 
major influence on the mineral content and 
architectural design of bone, and therefore 
its strength22. In a normal ambulatory child, 
the major bone strains result from muscle 
pull and growth. These factors are of 
paramount importance to chronically 
diseased children, in whom reduced 
mobility and thus muscle load is a major 
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cause of reduced bone mass and strength. 
This is most notable in children with 
neuromuscular disorders (Table 1). The 
most common site of fracture in children 
with reduced mobility is the distal femur 
(Figure 2). This is because their long bones 
tend to be slender with thin cortices and 
reduced trabecular density, and the lower 
limbs are usually more subjected to trauma 
from accidents or handling23-24. Vertebral 
compression fractures are less frequent, but 
if they occur they can be complicated by the 
development of scoliosis. 
 
 
 
Figure 2: Plain radiograph of the lower limb 
showing osteopenia and fracture in lower third of 
femur in a child with cerebral palsy. 
 
2. Disordered puberty 
Delayed or arrested pubertal development 
may occur as a result of an underlying 
chronic disease and/or its treatment, and 
unless assessed prospectively may be easily 
overlooked in the care of the affected child25. 
Pubertal hormones, estradiol in females and 
testosterone in males, influence longitudinal 
bone growth and bone mineral accrual, with 
their appropriate timing being important for 
normal skeletal development and the 
attainment of peak bone mass3,26-27. It is 
unclear if the induction of puberty in 
otherwise normal child with constitutional 
delay positively influences bone mass at 
final height. Androgen therapy does not 
however positively affect bone mass26.  
 
3. Malnutrition and abnormal body weight 
Adequate nutrition is essential for normal 
growth and development. It is not surprise-
ing; therefore, that osteoporosis is associated 
with malnutrition and low body weight 
disorders (Table 1)22. The cause of the 
osteoporosis in such disorders is 
multifactorial with interplay between low 
body weight, low calcium, vitamin D and 
protein intake, gonadal deficiency, growth 
hormone resistance and malabsorption28. 
Children during both health and disease 
should receive the recommended daily 
requirement of calcium. Without adequate 
sun exposure, even children living in sunny 
climates can become vitamin D deficient29. 
Because of this, the vitamin D status of 
chronically diseased children should be 
evaluated on an annual basis and if 
necessary, vitamin D supplementation 
commenced. 
Conversely, the obesity epidemic among 
youth is staggering. The overweight or 
obese children are undernourished in the 
sense that their diets are generally poor and 
lack many important nutrients. In addition, 
obesity itself is a risk factor for fractures in 
children30. Although it seems counterin-
tuitive, the data are convincing. Obese 
children are generally sedentary, causing 
poor musculoskeletal coordination and in-
adequate lean muscle mass to control their 
body mass. Because their bone development 
does not keep pace with their weight gain, 
their relatively immature skeletons must 
bear a disproportionate amount of weight 
when they fall and can result in fragility 
fractures30. 
 
4. Inflammatory cytokines and growth factors 
Systemic inflammatory disorders are 
frequently associated with osteopenia and 
osteoporosis. The cause of the bone loss is 
multifactorial, but increased circulating and 
focal concentrations of inflammatory cyto-
kines [interleukin-1 (IL-1), IL-6, IL-7, tumor 
necrosis factor-α‚ and receptor activator of 
Childhood osteoporosis 
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nuclear factor-κB ligand (RANKL)] and 
growth factors are likely to play an impor-
tant role28. Cytokines have been shown to 
stimulate osteoclastogenesis, suppress 
osteoblast recruitment and induce resistance 
to vitamin D, thus increasing bone 
resorption and decreasing bone formation28.
 
Table 1: Classification of childhood osteoporosis. Modified from Shaw8. 
 
5. Systemic glucocorticoids 
Glucocorticoids are commonly prescribed to 
children with chronic inflammatory and 
autoimmune disorders. Glucocorticoids are 
well known for their potent anti-inflam-
matory effects in patients with chronic 
Primary 
osteoporosis 
 
 Osteogenesis imperfecta 
 Idiopathic juvenile osteoporosis 
 Osteoporosis pseudoglioma syndrome 
 Others like Homocystinuria, Ehlers-Danlos Syndrome (type1)… 
Secondary 
osteoporosis 
 
Can be discussed under the following subheadings: 
Reduced mobility 
 
 Cerebral palsy 
 Spinal cord injury and spina bifida 
 Duchenne muscular dystrophy 
 Spinal muscle atrophy 
 Head injury 
 Unknown neurodisability 
Disordered puberty 
 
 Thalassemia major 
 Anorexia nervosa 
 Gonadal damage due to radiotherapy/ 
chemotherapy 
 Klinefelter’s syndrome 
 Galactosemia 
Malnutrition / abnormal 
body weight 
 
 Anorexia nervosa 
 Chronic systemic disease 
 Inflammatory bowel disease 
 Cystic fibrosis 
Inflammatory cytokines 
 Juvenile idiopathic arthritis 
 Systemic lupus erythematosis 
 Dermatomyositis 
 Inflammatory bowel disease 
Systemic glucocorticoids 
and other medications 
 
 Rheumatological conditions 
 Nephrotic syndrome 
 Leukemia 
 Organ and bone marrow transplantation 
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inflammatory disorders. One adverse effect 
of glucocorticoid use is its detrimental impact 
on BMD. At pharmacologic doses, glucocor-
ticoids impair the function and reduce the life 
of osteoblasts31. Simultaneously, glucocorti-
coids accelerate the maturation and activity 
of osteoclasts while exerting antiapoptotic 
effects on these cells32. In addition, 
glucocorticoids reduce intestinal calcium 
absorption and promote renal calcium 
excretion. Thus, chronic glucocorticoid 
therapy results in an increase in PTH 
secretion which promotes bone resorption29. 
Therefore, the combination of impaired bone 
formation and accelerated bone resorption 
increases risk of osteopenia and osteoporosis 
(Figure 3). 
 
 
 
Figure 3: Left femur demonstrates severe 
osteoporosis with marked loss of bone density in 
an older child on long standing steroid therapy. 
 
Vertebral compression fractures are the 
most prevalent fractures associated with 
glucocorticoid use in children. Gafni et al, 
showed that following the cessation of 
glucocorticoid therapy in young rabbits, 
growth and modeling allowed for steroid-
induced osteoporotic bone to be completely 
replaced by normal healthy bone33. This 
may provide another mechanism by which 
the bone health of the children studied by 
Leonard et al, improved between steroid 
doses34. These data also suggest that early in 
life, temporary insults to the child skeleton 
may not decrease peak bone mass. How-
ever, insults towards the end of the growing 
period may have more long lasting effects 
on bone integrity33. It is unclear if there is a 
safe, yet therapeutic, dose below which 
glucocorticoids do not adversely influence 
bone in children. Until this data is available, 
it is essential that children be prescribed the 
smallest effective dose of glucocorticoid and 
be withdrawn from it and commenced on 
steroid sparing medication as rapidly as 
possible. Alternate day dosing may prevent 
bone loss secondary to glucocorticoid use 
while maintaining therapeutic benefits, 
together with optimizing the intake of 
calcium and vitamin D3.  
 
6. Other medication 
Table 2 outlines other agents associated with 
childhood osteoporosis. The underlying 
mechanism responsible for the osteoporosis 
caused by these agents is unclear, and like 
glucocorticoids, much prospective research is 
required.  
As the number of survivors of childhood 
cancer increases, the toxic effects of 
chemotherapy and radiation on the skeleton 
are becoming more apparent. Osteoporosis is 
one of many health issues in a long list of 
potential “late effects” caused by these 
therapies35. Therefore, pediatrician must 
provide appropriate surveillance. Patients 
with disorders that require combination 
therapy and taking more than one agent at a 
time that may cause osteoporosis are at an 
even greater risk.  
 
Diagnosis 
 
The most obvious clinical manifestation of 
weak bones is a fracture after low-impact 
trauma. Chronic back pain in predisposed 
children may indicate vertebral compression 
fractures, but it is important to note that 
such fractures may also be asymptomatic, 
especially in those with increased risk for 
low BMD38. Conversely they may not be 
reported and remain under-diagnosed 
radiologically with false negative rates up to 
45%39. When a child with one or more risk 
factors for low BMD is identified, it is 
particularly important to measure BMD. 
Most Pediatric subspecialists are aware of 
the risks to skeletal health posed by various 
chronic diseases in their given fields of 
practice and routinely screen such patients 
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for evidence of low BMD using dual-energy 
x-ray absorptiometry (DXA) scans (Table 3). 
DXA is the most widely used technique to 
assess bone mass in children. Although great 
importance is often given to DXA, it should 
be remembered that there is no evidence that 
densitometric data can predict the likelihood 
of fracture in children-(Figure-4).
 
Table 2: Therapeutic agents associated with childhood osteoporosis. Modified from Munns 
and Cowell3. 
 
Therapeutic agent  Proposed mechanism for osteoporosis 
Methotrexate Uncertain. Impaired osteoblastic protein synthesis, abnormal vitamin C metabolism. 
Cyclosporine 
Uncertain. Possible dysregulation of the osteoprotegerin 
(OPG)-OPG ligand system with a resultant high turnover 
state36. 
Heparin 
Uncertain. a) Decreased 1-α-hydroxylase activity with 
reduced vitamin D and elevated PTH. b) direct effect on 
cancellous bone with an increase in bone resorption and 
decrease in bone formation. 
Radiotherapy Growth hormone deficiency, hypogonadism, AVN, muscle atrophy. 
Depot medroxyprogesterone 
acetate Central hypogonadism. 
Gonadotropin releasing 
hormone (GnRH) analogues Central hypogonadism. 
L-thyroxine suppressive 
therapy 
Increased bone resorption secondary to osteoblast mediated 
T3 osteoclast activation. 
Anti-convulsants 
Altered liver metabolism of 25-OH vitamin D25. Low BMD is 
also induced by the direct effects of anti-convulsant drugs on 
bone cells, resistance to PTH, inhibition of calcitonin secretion, 
and impaired calcium absorption37.  
 
Table 3: Indications for considering a dual-energy x-ray absorptiometry scan for children. 
Modified from Henwood and Binkovitz4. 
Risk factor for low bone mass density 
Chronic disease 
 Chronic renal insufficiency 
  Gastrointestinal diseases 
 Cystic fibrosis 
 Endocrine system disorders 
Medications or treatments  Glucocorticoids, anti-convulsant drugs, chemotherapy and radiotherapy 
Primary bone disease (i.e., osteogenesis imperfecta) 
Malnutrition 
Lifestyle habits  Lack of physical activity 
History of multiple fractures or a single fracture following low impact trauma 
Khalid I. Khoshhal 
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Figure 4: Lateral radiograph lumbar spine 
showing increased radiolucency of vertebra L1 – 
L4 with slightly radiodense endplates. DXA scan 
AP view lumbar spine showing BMD of 0.877 
g/cm2 with estimated Z-Score of -2.5 indicating 
established osteoporosis. 
The Z-score is the number of standard 
deviations (SD) of the patient's bone density 
above or below the values expected for the 
patient's age. By comparing the patient's 
BMD with the expected BMD for his or her 
age, the Z-score can help diagnose and 
classify osteoporosis, but it is by no means 
diagnostic by itself. Other patient factors 
should be taken into account, including 
height, weight, and physiological matu-
rity40,41. 
 Normal is a BMD that is within 1 SD of 
the young adult reference mean. 
 Osteopenia is a BMD between 1.0 and 2.5 
SD below the young adult reference mean. 
 Osteoporosis is a BMD more than 2.5 SD 
below the young adult reference mean42. 
BMD as assessed by DXA is not a true 
volumetric density, but rather, it is the mass 
of bone mineral per projection area 
(grams/cm2) and is given the term ‘areal 
BMD’ (aBMD). Areal BMD is a size-
dependent measure. Shorter children 
therefore have a reduced aBMD compared 
to age-matched controls. Children with 
secondary osteoporosis to chronic disease 
frequently have short stature resulting from 
their primary disease or its treatment, and 
may have a reduction in aBMD, not because 
there is anything abnormal with the 
composition or structure of their bones, but 
simply because the bones are small. Pubertal 
disturbance is another common problem 
associated with secondary osteoporosis and 
can result in an erroneous reduction in 
aBMD when comparing results to that of 
normally developed age-matched controls. 
This has led some authors to suggest that 
DXA results should be corrected for bone 
age and height when interpreting aBMD3. 
Methods to adjust for height and lean tissue 
mass have been described and can help 
determine if the osteopenia/osteoporosis is 
in part secondary to reduction in lean tissue 
or a primary disorder of bone. Chronic 
disease may have differential effects on 
cortical and trabecular bone dimensions and 
density. For example reduced mobility will 
have a major effect on bone strength of the 
lower limbs consisting predominantly of 
cortical bone, whereas chronic glucocor-
Childhood osteoporosis 
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ticoid therapy may preferentially affect the 
spine consisting predominantly of 
trabecular bone3,43-44. 
Another mode of assessing osteoporosis is 
ultrasound; by measuring the bone speed 
of sound at the tibial, radial, or calcaneal 
bones reflecting both cortical density and 
thickness9. In a recent study Alwis et al45, 
reported the use of broadband ultrasound 
attenuation in children and it seemed to be 
the quantitative ultrasound parameter that 
best resembled the changes in bone mineral 
content during growth. While ultrasound is 
being used more frequently in pediatrics 
especially for screening, DXA remains the 
gold standard as a diagnostic tool for 
osteoporosis. Comparison between both 
modalities in children is needed to see if 
ultrasound can be used for diagnosis as 
well. 
 
Role of biochemical markers of bone turnover 
Remodeling is a normal, natural process that 
maintains skeletal strength, enables repair of 
microfractures and is essential for calcium 
homeostasis. During the remodeling pro-
cess, osteoblasts synthesize a number of 
cytokines, peptides and growth factors that 
are released into the circulation. Their 
concentration thus reflects the rate of bone 
formation. Bone formation markers include 
serum osteocalcin, bone-specific alkaline 
phosphatase and procollagen-I carboxy-
terminal propeptide46. Osteoclasts produce 
bone degradation products that are also 
released into the circulation and are 
eventually cleared via the kidney. These 
include collagen cross-linking peptides and 
pyridinolines, which can be measured in the 
blood or urine and enable estimation of 
bone resorption rate. Bone resorption 
markers include urinary hydroxyproline, 
urinary pyridinoline, urinary deoxy-
pyridinoline as well as collagen Type I 
cross-linked N telopeptide and collagen 
Type I cross-linked C telopeptide47-49. Mark-
ers of bone formation and resorption are of 
value in estimating bone turnover rates. 
These biochemical markers may be used to 
identify fast bone losers50. The utility of 
bone markers to identify fast bone losers 
was prospectively evaluated in a large 
cohort of healthy postmenopausal women 
over four years50. It was not used to evaluate 
fast bone losers in children yet and this 
needs to be evaluated further. 
Higher levels of bone formation and 
resorption markers were significantly 
associated with faster and possibly greater 
BMD loss. In population studies, it appears 
that markers of bone resorption may be 
useful predictors of fracture risk and bone 
loss. Elevated bone resorption markers may 
be associated with an increased fracture risk 
in elderly women although the data are not 
uniform51. The association of markers of 
bone resorption with hip fracture risk in 
adults is independent of BMD, but a low 
BMD combined with high bone resorption 
biomarker doubled the risk associated with 
either of these factors alone51. However, the 
predictive value of biomarkers in assessing 
an individual child has not yet been 
confirmed. Biomarkers may be of value in 
predicting and monitoring response to 
potent antiresorptive therapy in clinical 
trials. Bone turnover markers may have a 
future role in the clinical management of 
osteoporosis. In population studies, the 
combination of low BMD and high bone 
turnover markers may provide a superior 
indication of fracture risk to either BMD or 
bone turnover markers alone51-52.  
 
Prevention 
 
Adult bone health is predominantly 
governed by two factors: (a) maximum 
attainment of peak bone mass; and (b) rate of 
bone loss which occurs with ageing. Both 
aspects are determined by a combination of 
endogenous and exogenous factors and, 
although genetic influences are believed to 
account for up to three-quarters of the 
variation in bone mass, there is still room for 
the modifiable factors (including nutrition) to 
play an important role53. The data support 
that both high physical activity —especially 
weight bearing exercise— and intake of 
adequate amounts of calcium and vitamin D 
are associated with a higher BMD, and 
attaining maximum bone mass particularly in 
adolescence because puberty is a critical time 
for accruing bone mass (peak adult bone 
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mass). Recent studies found that jumping-
based activities resulted in substantial 
improvements in bone mass in prepubertal 
and pubertal children54. The recommended 
dietary allowances of calcium have been 
fixed to 800 mg/d for prepubertal children 
(ages 4-8 years) and for adolescents (ages 9-18 
years) 1300 mg/d52. On the other hand, 
overweight showed the opposite effect. Diet 
habits and exercise must be considered as the 
main strategies to prevent adult osteoporosis 
during childhood55-56.  
To prevent bone loss secondary to reduced 
mobilization in children with chronic disease, 
weight-bearing activity should be 
maximized, which in healthy children and 
adolescents has been shown to increase bone 
mineral accrual and bone size57. For children 
with extreme bone fragility, swimming and 
hydrotherapy may be beneficial. In ambulant 
and non-ambulant children with spastic CP, 
weight-bearing activity has been shown to 
significantly improve femoral neck bone 
mineral content and volumetric BMD 
compared to controls58. In non-ambulant 
children with CP, a standing frame to 
facilitate an upright position has been shown 
to improve BMD, with the gains in BMD 
being proportional to the duration of 
standing3,59. 
 
Treatment 
 
The underlying principles of treatment of 
secondary osteoporosis in both children and 
adults is, where possible, to remove the 
underlying cause. Where this is not possible, 
minimizing the effects of treatment with 
drugs that adversely affect bone may be 
sufficient to eliminate any deterioration in 
bone quality. If this is not possible, the use of 
bone sparing drugs such as the 
bisphosphonates may be necessary whilst 
ensuring that attention is paid to optimizing 
calcium and vitamin D intake and 
encouraging mobility and exercise13.  
The measures outlined in the prevention 
section are frequently inadequate in pre-
venting the development of osteoporosis. In 
these situations, specific anti-osteoporosis 
therapy should be considered. While the 
guidelines for the treatment of osteoporosis 
in adults are widely accepted, the much less 
abundant data for children and adolescents 
with osteoporosis makes it harder to set clear 
guidelines for the pediatric population. 
Bisphosphonates are the most widely used 
medications for the treatment of childhood 
osteoporosis60. They are potent anti-
resorptive agents that disrupt osteoclastic 
activity33,61. Although bisphosphonates have 
been used for many years in adults, their 
systematic use in children has been limited. 
The majority of data pertaining to the clinical 
utility and mechanism of action of 
bisphosphonates in children comes from 
studies of cyclical intravenous pamidronate 
therapy in moderate to severe OI. The 
treatment of osteoporosis with bisphos-
phonates, specifically alendronate and 
pamidronate in pediatric cancer patients is 
described. Results showed that these 
medications were efficacious in reducing 
BMD loss during cancer therapy and were 
well tolerated in this special population62. In 
children and adolescents with OI, pami-
dronate therapy has been associated with 
improvements in muscle force, vertebral 
bone mass and size, bone pain, fracture rate 
and growth. In long bones, pamidronate has 
been shown to increase cortical thickness and 
improve bone strength15,63.  
Minodronate is a new nitrogen-containing 
bisphosphonate64. It was the first drug to 
demonstrate significant prevention of verte-
bral fractures in patients with osteoporosis in 
a phase III doubleblind comparative study. In 
vitro studies demonstrated that minodronate 
is one of the most potent inhibitors of bone 
resorption among currently available 
bisphosphonates. These data suggest that 
minodronate is a promising new potent 
bisphosphonate for the treatment of 
osteoporosis64. The use in children is not yet 
approved.  
The safety of bisphosphonate therapy 
continues to be of concern to many 
clinicians65. To allow for this issue to be 
systematically evaluated, it is of paramount 
importance that children and adolescents 
only receive bisphosphonates as part of well-
run clinical trials. Pamidronate lowers serum 
calcium concentrations that is most marked 
following the first infusion cycle15. In vitamin 
Childhood osteoporosis 
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D replete individuals receiving the 
recommended calcium intake, the hypo-
calcaemia is self-remitting15. The majority of 
children have an acute phase reaction "flu-
like” (fever, muscle pain, headache and 
vomiting) 12-36 hours following initial 
exposure to bisphosphonates which is self-
limiting66. It is unusual for this to recur with 
subsequent doses, and can be limited by pre-
treatment with paracetamol or ibuprofen66. 
Oral bisphosphonates may result in chemical 
esophagitis. Transient uveitis occurs in 
approximately 1% of children who receive 
pamidronate15. Bisphosphonates are also 
used for other diseases involving bone 
remodeling, such as IJO or familial hyper-
phosphatemia. The question of longterm side 
effects cannot be answered with the currently 
available data67. Because bisphosphonates 
accumulate in bone, they create a reservoir 
leading to continued release from bone for 
months or years after treatment is stopped. 
Studies with risedronate and alendronate 
suggest that if treatment is stopped after 3-5 
year, there is persisting antifracture efficacy, 
at least for 1-2 year. It is recommended to 
take a drug holiday after 5-10 year of 
bisphosphonate treatment. The duration of 
treatment and length of the holiday are 
based on fracture risk and pharmacokinetics 
of the bisphosphonate used. Patients at mild 
risk might stop treatment after 5 year and 
remain off as long as BMD is stable and no 
fractures occur. Higher risk patients should 
be treated for 10 year, have a holiday of no 
more than a year or two, and perhaps be on 
a non-bisphosphonate treatment during that 
time68. In general, as a substance group 
bisphosphonates are well tolerated and, 
when applied correctly, the toxicity is low. 
It was noticed that vitamin D insufficiency 
was remarkably common in children with 
primary and secondary osteopenia or 
osteoporosis. The inverse relationship 
between vitamin D and parathyroid horm-
one levels suggests a physiologic impact of 
insufficient vitamin D levels that may 
contribute to low bone mass or worsen the 
primary bone disease. It is suggested that 
monitoring and supplementation of vitamin 
D should be a priority in the management of 
children with osteopenia or osteoporosis69. 
It has been suggested that vitamin K2 
(which is found in meat, cheese and 
fermented products) may not only stimulate 
bone formation but also suppress bone 
resorption in vivo70. Clinically, vitamin K2 
sustains the lumbar BMD and prevents 
osteoporotic fractures in patients with age-
related osteoporosis and prevents vertebral 
fractures in patients with glucocorticoid-
induced osteoporosis. Even though the 
effect of vitamin K2 on the BMD is quite 
modest, this vitamin may have the potential 
to regulate bone metabolism and play a role 
in reducing the risk of osteoporotic 
fractures. Prabhoo et al53, reported vitamin 
K2 safety in children and suggested that it 
can be considered for prevention and 
treatment in those conditions known to 
contribute to osteoporosis. 
 
Specific disorders resulting in osteoporosis 
in children 
1. Cerebral palsy 
CP is a non-progressive encephalopathy 
with disordered posture and movement. 
Fracture incidence in children with CP is 
variously reported between 5 to 30%, with 
the majority of fractures occurring in the 
femoral shaft and supracondylar region21-22. 
Reduced mobility is the major cause for 
bone fragility in children with CP. Reduced 
mobility results in bone with a low bone 
mass and abnormal architectural design, 
which is unable to withstand the occasional 
mechanical challenges placed upon it, such 
as forceful muscle contractures associated 
with a convulsion or unusual weight 
bearing or transfer22. Other factors include 
vitamin D deficiency from reduced sunlight 
exposure and possibly anti-convulsant 
therapy, disorders of puberty and 
nutritional disorders. Lumbar spine BMD is 
often normal in children with CP who 
sustain a pathological fracture except in 
more involved children when spine is 
affected as well71.  
To prevent osteoporosis in children with CP 
a concerted effort must be made to maintain 
ambulation and weight bearing. As outlined 
above, biomechanical stimulation of bone 
requires further investigation as it holds 
great promise. Other general measures such 
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as ensuring adequate calcium and vitamin D 
intake and general nutrition, minimizing 
iatrogenic causes of bone loss and ensuring 
timely pubertal development are also 
important to the child with CP. Once 
osteoporosis is established, the use of 
bisphosphonate therapy is justified3. 
 
2. Leukemia 
The leukemias are the most common form of 
childhood malignancy. The two major 
skeletal complications of leukemia are 
osteoporosis and AVN72. Strauss et al, 
reported a 5-year cumulative fracture inci-
dence in children with acute lymphoblastic 
leukemia of 28%72. Risk factors for the 
development of skeletal complications in 
acute lymphoblastic leukemia include 
glucocorticoid administration, malnutri- 
tion, reduced mobility, methotrexate, cranial 
irradiation, impaired bone mineralization, 
older age at diagnosis and male sex22,72. The 
development of hypothyroidism, growth 
hormone deficiency and hypogonadism, 
may influence the bone health of children 
with leukemia and requires close 
monitoring22.  
 
3. Children with intellectual disabilities  
have increased risk factors associated with 
osteoporosis. It has been identified that this 
population has an increased prevalence of 
low BMD, osteoporosis and osteopenia73. 
The main contributory factors for low BMD 
are age, use of anti-convulsants, reduced 
mobilety and diagnosis of Down's 
syndrome. In most studies individuals with 
intellectual disabilities presented with 
more than two risk factors. It was identified 
in a survey that an increased prevalence of 
risk factors associated with osteoporosis, 
namely use of anti-convulsants (64%), 
reduced mobility (23%), history of falls 
(20%) and fractures (11%). Screening for the 
risk factors associated with low BMD in 
individuals with intellectual disabilities is 
important. If these are present further 
investigations should take place and those 
found to have osteopenia and osteoporosis 
should have treatment at an early stage to 
prevent morbidity and improve their 
quality of life73. 
Conclusion 
Osteoporosis as primary disorder or 
secondary to chronic disease is increasingly 
recognized major childhood health problem. 
With many factors influencing the bone 
health of children, the physician must take a 
broad approach to the prevention and 
treatment of bone disease. It is necessary to 
utilize nutritional, hormonal and 
biomechanical therapeutic regimes, as well 
as bisphosphonate therapy. With this 
approach and continued research, it may be 
possible to improve, not only the bone 
health of children, but also their general 
wellbeing and quality of their future life as 
adults and into old age. Osteoporosis in 
children is still a wide open area for 
research. 
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